M.J. Garlepp

1.5k total citations
38 papers, 1.2k citations indexed

About

M.J. Garlepp is a scholar working on Neurology, Epidemiology and Immunology. According to data from OpenAlex, M.J. Garlepp has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Neurology, 10 papers in Epidemiology and 10 papers in Immunology. Recurrent topics in M.J. Garlepp's work include Myasthenia Gravis and Thymoma (12 papers), Inflammatory Myopathies and Dermatomyositis (9 papers) and Peripheral Neuropathies and Disorders (5 papers). M.J. Garlepp is often cited by papers focused on Myasthenia Gravis and Thymoma (12 papers), Inflammatory Myopathies and Dermatomyositis (9 papers) and Peripheral Neuropathies and Disorders (5 papers). M.J. Garlepp collaborates with scholars based in Australia, United States and Canada. M.J. Garlepp's co-authors include Roger L. Dawkins, Frank Christiansen, P. J. Zilko, Peter Kay, Bruce Robinson, James McCluskey, Linda S. Manning, D. Neil Watkins, Philip J. Thompson and Mark R. Davis and has published in prestigious journals such as Annals of the New York Academy of Sciences, Immunological Reviews and International Journal of Cancer.

In The Last Decade

M.J. Garlepp

37 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.J. Garlepp Australia 18 397 253 199 185 184 38 1.2k
Michael J. Garlepp Australia 20 521 1.3× 391 1.5× 188 0.9× 315 1.7× 236 1.3× 36 1.5k
Otto Brændstrup Denmark 21 262 0.7× 161 0.6× 175 0.9× 129 0.7× 59 0.3× 50 994
Pia Svendsen Denmark 16 397 1.0× 154 0.6× 120 0.6× 87 0.5× 69 0.4× 30 1.1k
Yosuf El‐Shabrawi Austria 26 219 0.6× 201 0.8× 84 0.4× 128 0.7× 273 1.5× 97 1.8k
David G. Haegert Canada 24 692 1.7× 82 0.3× 107 0.5× 59 0.3× 109 0.6× 64 1.4k
Umberto Basile Italy 17 134 0.3× 187 0.7× 116 0.6× 99 0.5× 168 0.9× 106 1.0k
Kimito Kawahata Japan 18 584 1.5× 167 0.7× 55 0.3× 101 0.5× 259 1.4× 82 1.3k
Marilyn Campion United States 18 207 0.5× 190 0.8× 107 0.5× 419 2.3× 335 1.8× 25 1.7k
S Aotsuka Japan 22 464 1.2× 92 0.4× 46 0.2× 163 0.9× 635 3.5× 64 1.2k
José R. Manaligod United States 16 79 0.2× 173 0.7× 81 0.4× 78 0.4× 209 1.1× 38 921

Countries citing papers authored by M.J. Garlepp

Since Specialization
Citations

This map shows the geographic impact of M.J. Garlepp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.J. Garlepp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.J. Garlepp more than expected).

Fields of papers citing papers by M.J. Garlepp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.J. Garlepp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.J. Garlepp. The network helps show where M.J. Garlepp may publish in the future.

Co-authorship network of co-authors of M.J. Garlepp

This figure shows the co-authorship network connecting the top 25 collaborators of M.J. Garlepp. A scholar is included among the top collaborators of M.J. Garlepp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.J. Garlepp. M.J. Garlepp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Needham, Merrilee, Francis Mastaglia, & M.J. Garlepp. (2007). Genetics of inclusion‐body myositis. Muscle & Nerve. 35(5). 549–561. 34 indexed citations
2.
3.
Watkins, D. Neil, et al.. (1999). Expression and localization of COX-2 in human airways and cultured airway epithelial cells. European Respiratory Journal. 13(5). 999–999. 38 indexed citations
4.
Kok, Chee Choy, Emma Croager, Campbell S. Witt, et al.. (1999). Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex. Immunogenetics. 49(6). 508–516. 25 indexed citations
5.
Mastaglia, Francis, Beverley A. Phillips, P. J. Zilko, & M.J. Garlepp. (1999). Reply. Muscle & Nerve. 22(8). 1160–1161. 5 indexed citations
6.
Watkins, D. Neil, et al.. (1998). Expression and localization of the inducible isoform of nitric oxide synthase in nasal polyp epithelium. Clinical & Experimental Allergy. 28(2). 211–219. 34 indexed citations
7.
Fan, Ying, Miranda D. Grounds, M.J. Garlepp, & Manfred W. Beilharz. (1997). Increased survival, movement and fusion of myoblasts from sliced muscle grafts into skeletal muscle of T-cell depleted and tolerised host mice. UWA Profiles and Research Repository (University of Western Australia). 7. 231–240. 8 indexed citations
8.
Watkins, D. Neil, et al.. (1997). Expression and Activity of Nitric Oxide Synthases in Human Airway Epithelium. American Journal of Respiratory Cell and Molecular Biology. 16(6). 629–639. 107 indexed citations
9.
Upham, John W., M.J. Garlepp, Arthur W. Musk, & Bruce Robinson. (1995). Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.. Thorax. 50(8). 887–893. 23 indexed citations
10.
Garlepp, M.J., B.A. Laing, P. J. Zilko, William Ollier, & Francis Mastaglia. (1994). HLA associations with inclusion body myositis. Clinical & Experimental Immunology. 98(1). 40–45. 75 indexed citations
11.
Robinson, Bruce, Linda S. Manning, T.I. Christmas, et al.. (1993). The scientific basis for the immunotherapy of human malignant mesothelioma. European Respiratory Review. 3(11). 195–198. 10 indexed citations
12.
Mavaddat, Nasim, Bruce Robinson, Alison H. Rose, Linda S. Manning, & M.J. Garlepp. (1993). An analysis of the relationship between γδ T cell receptor V gene usage and non‐major histocompatibility complex‐restricted cytotoxicity. Immunology and Cell Biology. 71(1). 27–37. 8 indexed citations
13.
Davis, Mark R., Linda S. Manning, D. Whitaker, M.J. Garlepp, & Bruce Robinson. (1992). Establishment of a murine model of malignant mesothelioma. International Journal of Cancer. 52(6). 881–886. 156 indexed citations
14.
Dawkins, Roger L., et al.. (1987). HETEROGENEITY OF STEROID 21‐HYDROXYLASE GENES IN CLASSICAL CONGENITAL ADRENAL HYPERPLASIA. International Journal of Immunogenetics. 14(2-3). 89–98. 10 indexed citations
15.
Dawkins, Roger L., Peter Kay, M.J. Garlepp, & Frank Christiansen. (1987). Immunogenetics of Spontaneous, Drug‐Induced, and Experimental Myasthenia Gravis. Annals of the New York Academy of Sciences. 505(1). 398–406. 5 indexed citations
16.
Carroll, Graeme J., Robert Will, James B. Peter, M.J. Garlepp, & Roger L. Dawkins. (1987). Penicillamine induced polymyositis and dermatomyositis.. PubMed. 14(5). 995–1001. 41 indexed citations
17.
Cobain, T.J., James McCluskey, Alan N. Wilton, et al.. (1985). The Coexistence of IgA Deficiency and 21‐Hydroxylase Deficiency Marked by Specific MHC Supratypes. Annals of the New York Academy of Sciences. 458(1). 76–84. 11 indexed citations
18.
Garlepp, M.J., Peter Kay, B. R. H. Farrow, & Roger L. Dawkins. (1984). Autoimmunity in spontaneous myasthenia gravis in dogs. Clinical Immunology and Immunopathology. 31(2). 301–306. 15 indexed citations
19.
Garlepp, M.J., R.L. Dawkins, & Frank Christiansen. (1983). HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis.. BMJ. 286(6362). 338–340. 47 indexed citations
20.
Dawkins, Roger L., Frank Christiansen, Peter Kay, et al.. (1983). Disease Associations with Complotypes, Supratypes and Haplotypes. Immunological Reviews. 70(1). 5–22. 227 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael J. Garlepp Breakdown of academic impact, for papers by Otto Brændstrup Breakdown of academic impact, for papers by Pia Svendsen Breakdown of academic impact, for papers by Yosuf El‐Shabrawi Breakdown of academic impact, for papers by David G. Haegert Breakdown of academic impact, for papers by Umberto Basile Breakdown of academic impact, for papers by Kimito Kawahata Breakdown of academic impact, for papers by Marilyn Campion Breakdown of academic impact, for papers by S Aotsuka Breakdown of academic impact, for papers by José R. Manaligod
Rankless by CCL
2026